Compass Therapeutics Inc.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.235
- Today's High:
- $2.3
- Open Price:
- $2.27
- 52W Low:
- $1.81
- 52W High:
- $5.65
- Prev. Close:
- $2.26
- Volume:
- 118777
Company Statistics
- Market Cap.:
- $372.56 million
- Book Value:
- 1.387
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -16.51%
- Return on Equity TTM:
- -25.76%
Company Profile
Compass Therapeutics Inc. had its IPO on 2021-04-05 under the ticker symbol CMPX.
The company operates in the Healthcare sector and Biotechnology industry. Compass Therapeutics Inc. has a staff strength of 26 employees.
Stock update
Shares of Compass Therapeutics Inc. opened at $2.27 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.24 - $2.3, and closed at $2.27.
This is a +0.44% increase from the previous day's closing price.
A total volume of 118,777 shares were traded at the close of the day’s session.
In the last one week, shares of Compass Therapeutics Inc. have slipped by -4.62%.
Compass Therapeutics Inc.'s Key Ratios
Compass Therapeutics Inc. has a market cap of $372.56 million, indicating a price to book ratio of 4.684 and a price to sales ratio of 0.
In the last 12-months Compass Therapeutics Inc.’s revenue was $0 with a gross profit of $0 and an EBITDA of $-43373000. The EBITDA ratio measures Compass Therapeutics Inc.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Compass Therapeutics Inc.’s operating margin was 0% while its return on assets stood at -16.51% with a return of equity of -25.76%.
In Q1, Compass Therapeutics Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Compass Therapeutics Inc.’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.38 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Compass Therapeutics Inc.’s profitability.
Compass Therapeutics Inc. stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -11.0008. Its price to sales ratio in the trailing 12-months stood at 0.
Compass Therapeutics Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $187.98 million
- Total Liabilities
- $11.19 million
- Operating Cash Flow
- $4.27 million
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Compass Therapeutics Inc. ended 2024 with $187.98 million in total assets and $0 in total liabilities. Its intangible assets were valued at $187.98 million while shareholder equity stood at $175.27 million.
Compass Therapeutics Inc. ended 2024 with $0 in deferred long-term liabilities, $11.19 million in other current liabilities, 13000.00 in common stock, $-280651000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $27.03 million and cash and short-term investments were $175.17 million. The company’s total short-term debt was $1,122,000 while long-term debt stood at $0.
Compass Therapeutics Inc.’s total current assets stands at $183.60 million while long-term investments were $0 and short-term investments were $148.14 million. Its net receivables were $320000.00 compared to accounts payable of $1.13 million and inventory worth $0.
In 2024, Compass Therapeutics Inc.'s operating cash flow was $4.27 million while its capital expenditure stood at $0.
Comparatively, Compass Therapeutics Inc. paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.27
- 52-Week High
- $5.65
- 52-Week Low
- $1.81
- Analyst Target Price
- $9.05
Compass Therapeutics Inc. stock is currently trading at $2.27 per share. It touched a 52-week high of $5.65 and a 52-week low of $5.65. Analysts tracking the stock have a 12-month average target price of $9.05.
Its 50-day moving average was $2.59 and 200-day moving average was $3.44 The short ratio stood at 7.83 indicating a short percent outstanding of 0%.
Around 1566.3% of the company’s stock are held by insiders while 6329% are held by institutions.
Frequently Asked Questions About Compass Therapeutics Inc.
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company’s product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.